TOMTOM
25.10.2016 07:32:28 CEST | Business Wire | Press release
Marking a significant milestone for its Consumer business, TomTom (TOM2 ) today announces a major advertising campaign supporting TomTom Sports: Get Going . The campaign reinforces TomTom’s commitment to continue to launch Sports Wearables that inspire people to move. Created in partnership with Amsterdam-based agency Pool Worldwide, the campaign spans global markets with television, cinema, print, digital and out of home ad placements.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024006174/en/
“Since 2011 we’ve set out to create Sports products that inspire people to move by taking away barriers and celebrating achievements. We were the first to integrate an optical Heart-Rate monitor into a GPS running watch and by integrating a music player we empowered people to leave increasingly larger and heavier phones at home. We have recently launched the world’s first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist – answering the age-old question ‘is what I’m doing, doing anything for me’. Today we’re incredibly proud to launch the Get Going campaign to further strengthen the TomTom Sports brand.” said Corinne Vigreux, Co-Founder and Managing Director, TomTom Consumer.
Patrick Stal, VP of Marketing for TomTom Sports adds: “This campaign marks a milestone for our brand. It showcases a TomTom Sports brand that caters to the needs of audiences ranging from those that are taking their first step down the road, to those that are stepping over the starting line of their first marathon. We are claiming a unique space in the world of sports. TomTom Sports is not here to shout at you to beat the impossible, be unstoppable, go harder, tougher, longer, deeper, rougher or sweatier. Let other sports brands do that. We want to help people where they need it most. Right at the beginning, where excuses often beat conviction. We want to be the brand that inspires people to Get Going and take that first step, no matter how big or small their effort might be, time and time again.”
For more information, visit http://getgoing.tomtom.com/en_gb .
Watch the hero ad here .
Credits:
End responsible at TomTom: Patrick Stal, Kelly McConville
Concept: Pool Worldwide
Creative Strategy: Pool Worldwide
Account: Pool Worldwide
RTV Producer: Sio van Bochove
Production Company: Pool Worldwide
Director: Paul Meijer
Producer: Sio van Bochove
Editor: Robert van Ees
Post production: The Ambassadors
Sound studio: The Ambassadors
-ENDS-
About TomTom Sports
TomTom Sports is on a mission to help you get going.
Since 2011, we’ve developed Sports and Fitness products that make it easier to get moving.
We were the first to add an optical heart-rate monitor to a GPS Sports Watch with TomTom Cardio , and by integrating a music player into our Sports Watches have enabled you to leave your smartphone at home. We’ve always been focused on innovating to make it easier to get going.
We also recently launched TomTom Touch , the first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist, technology usually reserved for elite athletes.
Find the full TomTom Sports product lineup here .
About TomTom
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can achieve more.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We serve four different markets: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006174/en/
Contact:
TomTom
Media
Lindsay Mandeville
+31 6 11
334292
lindsay.mandeville@tomtom.com
or
Investor
Relations
Bisera Grubesic
+31 20 75 75 194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom